{"chunk_id": "m2-qos-2.3-overview-001", "module": "2.3", "section": "2.3", "title": "Quality Overall Summary (QOS) overview", "text": "QOS provides a concise summary of Module 3 data and should not introduce new information. Highlight critical parameters, justify deviations from guidelines, and cross-reference other modules. Recommended length: <=40 pages of text (<=80 pages for complex/biotech products).", "source": "m2.pdf", "page": [1]}
{"chunk_id": "m2-qos-2.3-introduction-001", "module": "2.3", "section": "2.3.INTRODUCTION", "title": "Introduction", "text": "Include proprietary and non‑proprietary names of the drug substance, company name, dosage form(s), strength(s), route of administration, and proposed indication(s).", "source": "m2.pdf", "page": [1]}
{"chunk_id": "m2-qos-2.3.s.1-001", "module": "2.3", "section": "2.3.S.1", "title": "Drug Substance — General Information", "text": "Summarize key general information from 3.2.S.1 (e.g., nomenclature, structure, general properties).", "source": "m2.pdf", "page": [1]}
{"chunk_id": "m2-qos-2.3.s.2-001", "module": "2.3", "section": "2.3.S.2", "title": "Drug Substance — Manufacture", "text": "Summarize 3.2.S.2: manufacturer information; brief description of the manufacturing process including starting materials, critical steps, reprocessing, and controls; provide/process flow diagram; describe source and starting materials of biological origin; justify critical steps, process controls, and acceptance criteria; describe process validation/evaluation; summarize major manufacturing changes during development and cross‑refer to affected nonclinical/clinical batches.", "source": "m2.pdf", "page": [1]}
{"chunk_id": "m2-qos-2.3.s.3-001", "module": "2.3", "section": "2.3.S.3", "title": "Drug Substance — Characterisation", "text": "For NCE: summarise evidence of structure and isomerism (3.2.S.3.1). For chiral substances, specify the stereoisomer used in development and for marketing. For Biotech: describe desired product and product‑related substances and summarise characterisation data (e.g., structure, biological activity). For both: summarise impurity data, basis for acceptance criteria, impurity levels in development and commercial batches, and how impurity limits are qualified.", "source": "m2.pdf", "page": [2]}
{"chunk_id": "m2-qos-2.3.s.4-001", "module": "2.3", "section": "2.3.S.4", "title": "Drug Substance — Control of Drug Substance", "text": "Provide a brief justification of specification(s), analytical procedures, and validation. Include specification from 3.2.S.4.1 and a tabulated summary of batch analyses from 3.2.S.4.4 with graphs where appropriate.", "source": "m2.pdf", "page": [2]}
{"chunk_id": "m2-qos-2.3.s.5-001", "module": "2.3", "section": "2.3.S.5", "title": "Drug Substance — Reference Standards or Materials", "text": "Summarize information from 3.2.S.5; use tabulated presentation where appropriate.", "source": "m2.pdf", "page": [2]}
{"chunk_id": "m2-qos-2.3.s.6-001", "module": "2.3", "section": "2.3.S.6", "title": "Drug Substance — Container Closure System", "text": "Provide a brief description and discussion of the 3.2.S.6 information.", "source": "m2.pdf", "page": [2]}
{"chunk_id": "m2-qos-2.3.s.7-001", "module": "2.3", "section": "2.3.S.7", "title": "Drug Substance — Stability", "text": "Summarize stability studies (conditions, batches, analytical procedures), results and conclusions, proposed storage conditions and retest date or shelf‑life (3.2.S.7.1). Include post‑approval stability protocol (3.2.S.7.2) and tabulated summary of stability results (3.2.S.7.3) with graphs where relevant.", "source": "m2.pdf", "page": [2]}
{"chunk_id": "m2-qos-2.3.p.1-001", "module": "2.3", "section": "2.3.P.1", "title": "Drug Product — Description and Composition", "text": "Provide information and composition from 3.2.P.1: dosage form description, full component list with amounts per unit (including overages) and functions, any reconstitution diluent, and container/closure.", "source": "m2.pdf", "page": [3]}
{"chunk_id": "m2-qos-2.3.p.2-001", "module": "2.3", "section": "2.3.P.2", "title": "Drug Product — Pharmaceutical Development", "text": "Discuss information/data from 3.2.P.2. Provide tabulated summary of clinical formulation compositions and dissolution profiles where relevant.", "source": "m2.pdf", "page": [3]}
{"chunk_id": "m2-qos-2.3.p.3-001", "module": "2.3", "section": "2.3.P.3", "title": "Drug Product — Manufacture", "text": "Summarize 3.2.P.3: manufacturer information; brief description of the manufacturing process and controls to ensure consistent quality; flow diagram per 3.2.P.3.3; brief description of process validation/evaluation per 3.2.P.3.5.", "source": "m2.pdf", "page": [3]}
{"chunk_id": "m2-qos-2.3.p.4-001", "module": "2.3", "section": "2.3.P.4", "title": "Drug Product — Control of Excipients", "text": "Include a brief summary on quality of excipients as described in 3.2.P.4.", "source": "m2.pdf", "page": [3]}
{"chunk_id": "m2-qos-2.3.p.5-001", "module": "2.3", "section": "2.3.P.5", "title": "Drug Product — Control of Drug Product", "text": "Provide brief justification of specification(s), summary of analytical procedures and validation, and characterisation of impurities. Include specification(s) from 3.2.P.5.1 and tabulated summary of batch analyses from 3.2.P.5.4 with graphs where appropriate.", "source": "m2.pdf", "page": [3]}
{"chunk_id": "m2-qos-2.3.p.6-001", "module": "2.3", "section": "2.3.P.6", "title": "Drug Product — Reference Standards or Materials", "text": "Summarize information from 3.2.P.6; tabulate where appropriate.", "source": "m2.pdf", "page": [3]}
{"chunk_id": "m2-qos-2.3.p.7-001", "module": "2.3", "section": "2.3.P.7", "title": "Drug Product — Container Closure System", "text": "Provide a brief description and discussion of 3.2.P.7 information.", "source": "m2.pdf", "page": [3]}
{"chunk_id": "m2-qos-2.3.p.8-001", "module": "2.3", "section": "2.3.P.8", "title": "Drug Product — Stability", "text": "Summarize stability studies and conclusions, including storage conditions, shelf‑life, in‑use conditions if applicable. Provide tabulated summary of results (3.2.P.8.3) and post‑approval stability protocol (3.2.P.8.2).", "source": "m2.pdf", "page": [3]}
{"chunk_id": "m2-qos-2.3.a.1-001", "module": "2.3", "section": "2.3.A.1", "title": "Appendices — Facilities and Equipment (Biotech)", "text": "Provide a summary of facility information described under 3.2.A.1 (applicable to biotech products).", "source": "m2.pdf", "page": [4]}
{"chunk_id": "m2-qos-2.3.a.2-001", "module": "2.3", "section": "2.3.A.2", "title": "Appendices — Adventitious Agents Safety Evaluation", "text": "Discuss measures implemented to control endogenous and adventitious agents in production. Provide tabulated summary of reduction factors for viral clearance from 3.2.A.2.", "source": "m2.pdf", "page": [4]}
{"chunk_id": "m2-qos-2.3.a.3-001", "module": "2.3", "section": "2.3.A.3", "title": "Appendices — Excipients", "text": "Refer to excipient‑related appendices as appropriate.", "source": "m2.pdf", "page": [4]}
{"chunk_id": "m2-qos-2.3.r-001", "module": "2.3", "section": "2.3.R", "title": "Regional Information", "text": "Provide brief region‑specific information as per section 3.2.R, where appropriate.", "source": "m2.pdf", "page": [4]}
